APTAFRAME · DNA-origami frame platform for co-evolution ligand selection
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-04-01 → 2021-03-31
- EU contribution
- €212,934
- Participants
- 1
- Scheme
- MSCA-IF-EF-RI
Lines connect the coordinator with its partners.
Results in brief
DNA-origami frame platform for co-evolution ligand selection
The humoral immune system is a key aspect of human biology in fighting off diseases and eliminating pathogens. Furthermore, engineered antibodies can fight an increasing number of diseases including cancer and autoimmune conditions. Therefore, strategies to systematically and efficiently generate high-affinity antibodies are important parts of modern biotechnology. However, methods of rapidly creating antibodies binding to a very specific region of a target remains challenging and a major unmet goal. New methods of selection, based on spatial control over affinity reagent discovery process should therefore accelerate and increase efficiency of antibody discovery. The overall aim of APTAFRAME was to build a novel technology platform for the systematic discovery of ligands leveraging cooperative binding effects in the context of spatially configurable DNA origami frameworks and to initially demonstrate this in the context of nucleic acid aptamer libraries. As a next step, APTAFRAME envisaged to evolve aptamers composed of macrocyclic peptides (MCP) and antibodies against proteins of interest using co-evolution as a driver for cooperative binding. The best method to display peptides on the DNA origami frames is through ribosome display. Protein discovery through ribosome display relies on the reading of a messenger RNA (mRNA) that also serves as sequence-to-protein connector during high-throughput readout. Unfortunately, the chemical (and biological) degradability of RNA poses a challenge for the development of this, and similar methodologies. Xenonucleic acids (XNAs) are alternative informational polymers largely resistant to chemical and biological degradation. Unfortunately, current ribosomes cannot efficiently translate peptides and proteins from mXNAs. We have therefore focused part of our efforts trying to circumvent this problem by creating ribosomes that can read genetic information encoded in mXNAs. Our hope is that by producing mXNA dependent ribosomes we will create a robust system for the decoration of DNA nano-objects with translated peptides and proteins utilised as a framework for cooperative evolution.
Data: CORDIS, © European Union
Project objective
Affinity reagents such as antibodies and aptamers are of paramount importance as tools in biotechnology and the treatment of a wide range of diseases. However, despite their scientific and economAffinity reagents such as antibodies and aptamers are of paramount importance as tools in biotechnology and the treatment of a wide range of diseases. However, despite their scientific and economic impact it remains challenging to systematically generate high-affinity ligands to cover all epitopes of a given target. Here I propose a strategy to provide spatial control over ligand discovery process leveraging the power of in vitro evolution in conjunction with the spatial addressability of DNA nanotechnology methods. Together they form a new discovery platform for the systematic and parallel generation of ligands, specifically aptamers and single-chain Fv antibody fragments (scFv), to provide coverage of epitopes at predefined targets. The proposed strategy exploits cooperative binding (avidity), by co-evolution of the affinity reagents, in the context of a defined molecular three-dimensional framework provided by DNA origami structures. This further expedites structure determination of ligand-target complexes by cryo-electron microscopy (cryo-EM). The combination of rational framework design, in vitro evolution and structural feedback provided by cryo-EM reconstructions will provide a toolbox for the systematic generation of ligands to all accessible epitopes. Our approach also provides a tool for electron microscopy reconstruction of smaller (< 100kDa) biomolecules and their molecular interactions by enhancing contrast and providing context. Once established, this approach will provide a transformational technology platform that enables the parallel interrogation of multidimensional, spatially resolved libraries, yielding cooperative ligands for highly specific target recognition, with direct applications in biosensor development, proteome analysis, diagnostics and therapy.
Original text from CORDIS.
Participants
- UNITED KINGDOM RESEARCH AND INNOVATION · SWINDONCoordinatorUnited Kingdom
Links
- View on CORDIS
- DOI: 10.3030/845303
- https://www2.mrc-lmb.cam.ac.uk/group-leaders/h-to-m/philipp-holliger/
Data: CORDIS, © European Union
